Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment

• Autores: Porrás, Analía I; Yadón, Zaida E.; Altcheh, Jaime; Britto, Constança; Chaves, Gabriela C; Flevaud, Laurence; Martins-Filho, Olindo Assis; Ribeiro, Isabela; Schijman, Alejandro G.; Shikanai-Yasuda, Maria Aparecida; Sosa-Estani, Sergio; Stobbaerts, Eric; Zicker, Fabio
• Año de publicación: 2015
• Idioma: inglés
• Tipo de recurso: artículo
• Fuente: PLoS neglected tropical diseases 2015; 9(6):e0003697.
• Materia: Trypanosoma cruzi; Enfermedad de Chagas
• Institución: Administración Nacional de Laboratorios e Institutos de Salud "Dr. Carlos G. Malbrán"

Fil: Porrás, Analía I. Pan American Health Organization, Regional Office of the World Health Organization, Washington, D.C.; Estados Unidos.
Fil: Yadón, Zaida E. Pan American Health Organization, Regional Office of the World Health Organization, Washington, D.C.; Estados Unidos.
Fil: Altcheh, Jaime. Servicio de Parasitología y Chagas, Hospital de Niños Ricardo Gutiérrez, Ciudad de Buenos Aires; Argentina.
Fil: Britto, Constança. Laboratório de Biologia Molecular e Doenças Endêmicas, Oswaldo Cruz Institute, Laboratory of Molecular Biology and Endemic Diseases, FIOCRUZ, Rio de Janeiro; Brasil.
Fil: Chaves, Gabriela C. Sergio Arouca National School of Public Health, FIOCRUZ, Rio de Janeiro; Brasil.
Fil: Flevaud, Laurence. Médecins Sans Frontières-Médecins Sans Frontières Operational Center Barcelona-Athens (OCBA), Barcelona; España.
Fil: Martins-Filho, Olindo Assis. René Rachou Research Center, Laboratory of Biomarkers of Diagnostic and Monitoring, Oswaldo Cruz Institute, Minas Gerais; Brasil.
Fil: Ribeiro, Isabela. Latin America Regional Office, Drugs for Neglected Diseases initiative, Rio de Janeiro; Brasil.
Fil: Schijman, Alejandro G. Laboratorio de Biología Molecular de la Enfermedad de Chagas, Instituto de Investigaciones en Ingeniería Genética y Biología Molecular "Dr Hector Torres" (INGEBI-CONICET), Buenos Aires; Argentina.
Fil: Shikanai-Yasuda, Maria Aparecida. Department of Infectious and Parasitic Diseases, Faculdade de Medicina, University of São Paulo, Sao Paulo; Brasil.
Fil: Sosa-Estani, Sergio. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Parasitología; Argentina.
Fil: Stobbaerts, Eric. Latin America Regional Office, Drugs for Neglected Diseases initiative, Rio de Janeiro; Brasil.
Fil: Zicker, Fabio. Center for Technological Development in Health, Oswaldo Cruz Foundation, (FIOCRUZ), Rio de Janeiro; Brasil.
Chagas disease, or American trypanosomiasis, affects 8 million people, largely in Latin America, where it is endemic in all countries. With an overall estimate of 65 million people at risk of contracting the disease, 28,000 new cases every year, and 12,000 deaths annually, Chagas disease is the most important parasitic disease in the Americas [1]. In addition, nonendemic countries such as the United States [2,3], Canada [4], Germany [5], Italy [6], Spain [7,8], Switzerland [9,10], and France [11] have experienced the occurrence of Trypanosoma cruzi–infected and Chagas disease cases; the majority of these cases are among immigrants coming from endemic Latin American countries [12]. Like other neglected tropical diseases (NTDs), Chagas disease affects mostly poor populations with limited access to health services. Vector transmission is associated with poor housing in periurban and rural areas. After infection, the disease is characterized by an acute phase, usually asymptomatic, which evolves in 20%–30% of the patients to a chronic disabling cardiac and/or digestive clinical form. The remaining infected individuals evolve to a chronic asymptomatic but infective clinical phase [13]. Reactivation of chronic Chagas disease may occur associated with comorbidities such as HIV/AIDS, organ transplants, or immunosuppressive therapy [14].